KR102955500B1 - 건선성 관절염의 치료 방법 - Google Patents
건선성 관절염의 치료 방법Info
- Publication number
- KR102955500B1 KR102955500B1 KR1020207036941A KR20207036941A KR102955500B1 KR 102955500 B1 KR102955500 B1 KR 102955500B1 KR 1020207036941 A KR1020207036941 A KR 1020207036941A KR 20207036941 A KR20207036941 A KR 20207036941A KR 102955500 B1 KR102955500 B1 KR 102955500B1
- Authority
- KR
- South Korea
- Prior art keywords
- treatment
- pharmaceutical composition
- compound
- psoriatic arthritis
- score
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1808575.3A GB201808575D0 (en) | 2018-05-24 | 2018-05-24 | Methods for the treatment of psoriatic arthrits |
| GB1808575.3 | 2018-05-24 | ||
| PCT/EP2019/063283 WO2019224283A1 (en) | 2018-05-24 | 2019-05-23 | Methods for the treatment of psoriatic arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210013168A KR20210013168A (ko) | 2021-02-03 |
| KR102955500B1 true KR102955500B1 (ko) | 2026-04-21 |
Family
ID=62812304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207036941A Active KR102955500B1 (ko) | 2018-05-24 | 2019-05-23 | 건선성 관절염의 치료 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12329758B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3801548A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2021524472A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102955500B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112203660B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019273664B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3101386A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201808575D0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA52738A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019224283A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| AU2021308574A1 (en) * | 2020-07-13 | 2023-03-09 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody |
| EP4287299A4 (en) | 2021-01-29 | 2025-01-01 | LG Chem, Ltd. | ELECTRODE |
| EP4305062A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1156037B1 (en) | 1999-01-29 | 2004-12-01 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| US20040138285A1 (en) | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| WO2004039816A1 (ja) | 2002-10-29 | 2004-05-13 | Shionogi & Co., Ltd. | セフェム化合物の無機酸塩の結晶 |
| EP1601672B1 (en) | 2003-02-14 | 2006-07-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US20070004658A1 (en) | 2004-06-21 | 2007-01-04 | Nick Vandeghinste | Method and means for treatment of osteoarthritis |
| MX2007002050A (es) | 2004-08-18 | 2007-03-29 | Pharmacia & Upjohn Co Llc | Compuestos de triazolopiridina. |
| EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
| JP5352476B2 (ja) | 2007-06-05 | 2013-11-27 | 武田薬品工業株式会社 | キナーゼ阻害剤としての二環式複素環化合物 |
| CN101801966A (zh) | 2007-07-18 | 2010-08-11 | 诺瓦提斯公司 | 双环杂芳基化合物和它们作为激酶抑制剂的用途 |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| US20110124692A1 (en) | 2008-07-31 | 2011-05-26 | Daiichi Sankyo Company, Limited | Crystalline forms of thiazolidinedione compound and its manufacturing method |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JP2013049632A (ja) | 2011-08-30 | 2013-03-14 | Kowa Co | ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び/又は治療剤 |
| SA112330992B1 (ar) | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| MX368511B (es) * | 2012-06-22 | 2019-10-07 | Galapagos Nv | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma. |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| KR20170134750A (ko) * | 2015-04-13 | 2017-12-06 | 갈라파고스 엔.브이. | 염증 질환의 치료 방법 |
| SMT202300328T1 (it) | 2015-04-13 | 2023-11-13 | Galapagos Nv | Metodi per il trattamento di disturbi cardiovascolari |
| US20170173034A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| FI3595667T3 (fi) * | 2017-03-14 | 2024-01-12 | Galapagos Nv | Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta |
-
2018
- 2018-05-24 GB GBGB1808575.3A patent/GB201808575D0/en not_active Ceased
-
2019
- 2019-05-23 KR KR1020207036941A patent/KR102955500B1/ko active Active
- 2019-05-23 MA MA052738A patent/MA52738A/fr unknown
- 2019-05-23 CA CA3101386A patent/CA3101386A1/en active Pending
- 2019-05-23 AU AU2019273664A patent/AU2019273664B2/en active Active
- 2019-05-23 EP EP19726950.9A patent/EP3801548A1/en active Pending
- 2019-05-23 WO PCT/EP2019/063283 patent/WO2019224283A1/en not_active Ceased
- 2019-05-23 CN CN201980034599.1A patent/CN112203660B/zh active Active
- 2019-05-23 JP JP2020565417A patent/JP2021524472A/ja active Pending
- 2019-05-23 US US17/057,946 patent/US12329758B2/en active Active
-
2024
- 2024-02-16 JP JP2024021644A patent/JP7751362B2/ja active Active
-
2025
- 2025-04-22 AU AU2025202777A patent/AU2025202777A1/en active Pending
- 2025-05-13 US US19/206,213 patent/US20260108530A1/en active Pending
- 2025-09-24 JP JP2025157844A patent/JP2025183397A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| Annals of the Rheumatic Diseases, 2017, Vol.76, Suppl.2, pp.118-119 (DOI: 10.1136/annrheumdis-2017-eular.1977)* |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019224283A1 (en) | 2019-11-28 |
| US20260108530A1 (en) | 2026-04-23 |
| JP7751362B2 (ja) | 2025-10-08 |
| CA3101386A1 (en) | 2019-11-28 |
| AU2025202777A1 (en) | 2025-05-08 |
| EP3801548A1 (en) | 2021-04-14 |
| JP2021524472A (ja) | 2021-09-13 |
| JP2024069223A (ja) | 2024-05-21 |
| MA52738A (fr) | 2021-04-14 |
| AU2019273664A1 (en) | 2021-01-21 |
| JP2025183397A (ja) | 2025-12-16 |
| US12329758B2 (en) | 2025-06-17 |
| US20210299135A1 (en) | 2021-09-30 |
| CN112203660B (zh) | 2024-12-31 |
| KR20210013168A (ko) | 2021-02-03 |
| AU2019273664B2 (en) | 2025-01-23 |
| GB201808575D0 (en) | 2018-07-11 |
| CN112203660A (zh) | 2021-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7751362B2 (ja) | 乾癬性関節炎の治療方法 | |
| US11993605B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
| US9345702B2 (en) | Methods of treatment using selective Bcl-2 inhibitors | |
| US20220251105A1 (en) | Methods of treating a mk2-mediated disorder | |
| US11524964B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | |
| US20220267342A1 (en) | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | |
| US11780848B2 (en) | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof | |
| US20190314382A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases | |
| US20250195476A1 (en) | Jak1 pathway inhibitors for the treatment of prurigo nodularis | |
| Hardy et al. | Clinical profile of methotrexate-resistant juvenile localised scleroderma | |
| JP2022549379A (ja) | ウパダシチニブによる脊椎関節炎及び乾癬状態の治療 | |
| Hawkins | 54 Rheumatoid Arthritis and Osteoarthritis | |
| TW202521113A (zh) | 類風濕性關節炎治療藥 | |
| EA050830B1 (ru) | Ингибиторы пути jak1 для лечения узловатой почесухи | |
| HK40082153A (en) | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| F13 | Ip right granted in full following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |